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Using 3D telomere quantitative fluorescence in situ hybridization, we determined the 3D telomere organization of
74 neuroblastoma tissue samples. Hierarchical cluster analysis of the measured telomere parameters identified
three subgroups from our patient cohort. These subgroups have unique telomere profiles based on telomere
length and nuclear architecture. Subgroups with higher levels of telomere dysfunction were comprised of tumors
with greater numbers of telomeres, telomeric aggregates, and short telomeres (P b .0001). Tumors with greater
telomere dysfunction were associated with unfavorable tumor characteristics (greater age at diagnosis,
unfavorable histology, higher stage of disease, MYCN amplification, and higher MYCN expression) and poor
prognostic risk (P b .001). Subgroups with greater telomere dysfunction also had higher intratumor heterogeneity.
MYCN overexpression in two neuroblastoma cell lines with constitutively low MYCN expression induced changes
in their telomere profile that were consistent with increased telomere dysfunction; this illustrates a functional
relationship between MYCN and 3D telomere organization. This study demonstrates the ability to classify
neuroblastomas based on the level of telomere dysfunction, which is a novel approach for this cancer.
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Neuroblastoma is the most common extracranial malignancy in children.
This neoplasm is characterized by both clinical and molecular
heterogeneity, and the prognostic risk calculation is multifactorial. The
most important parameters predictive of an unfavorable outcome include
MYCN amplification [1,2], MYCN protein overexpression [3,4], age
greater than 18 months at diagnosis [5,6], loss of chromosome arm 1p
[7,8] and 11q [9], and gain of chromosome arm 17q [10].
Neuroblastomas have been subgrouped according to their pattern of
chromosomal instability: whereas some tumors exhibit numerical and fewor
no structural aberrations, others are dominated by structural rearrangements,
including intrachromosomal rearrangements [11,12]. Chromosome insta-
bility has been linked to telomere length aberrations in many cancers,
including neuroblastoma [12,13]. However, there have been conflicting
findings on whether an increase, decrease, or unchanging telomere length is
associatedwith a better outcome [13–15]. These inconclusive resultsmay be
due to themethods employed tomeasure telomere length, wherein only the
average telomere length for each cell was determined.
Nuclear architecture is key to cellular function [16], and changes in
nuclear architecture contribute to the pathogenesis and progression ofcancer [17]. Our laboratory developed a method of analyzing the
interphase nuclear organization of telomeres as a novel and more
in-depth approach to study telomere length and telomere dysfunction
in disease [18]. Our method uses 3D quantitative fluorescence in situ
hybridization (Q-FISH) to label all telomeres in interphase nuclei
while preserving the nuclear architecture of the sample. Our software
measures multiple telomere parameters for each cell including the
number of telomeres, the length of each telomere, the number of
Table 1. Neuroblastoma Cohort Characteristics
Cases (n)
Stage
1 13
2 11
3 8
4 30
4S 11
Unknown 1
Histology
Favorable 28
Unfavorable 35
Unknown 11
Age at diagnosis
b18 months 41
N18 months 33
MYCN amplification
No 63
Yes 11
MYCN expression
Low 43
Medium 20
High 11
COG risk score
Low 36
Intermediate 8
High 28
Unknown 2
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of the telomeres [18,19]. These measurements create a telomere
profile unique to an individual sample. Increases in the number of
telomeres, telomeric aggregates, and short telomeres are frequently
associated with tumor compared to nontumor cells, aggressive forms
of disease, and poor patient outcomes [19–22].
In this study, we examined for the first time the 3D telomere
organization in 74 archived neuroblastoma tissue samples. Using
hierarchical cluster analysis of the measured telomere parameters, we
identified three tumor subgroups representing unique levels of
telomere dysfunction. We found that tumors with greater telomere
dysfunction were associated with unfavorable tumor characteristics
including MYCN amplification and higher MYCN expression. To
test the hypothesis that high levels of MYCN present in a subgroup of
patients (11/74) lead to increased telomere dysfunction, we over-
expressed MYCN in two neuroblastoma cell lines with constitutively
low MYCN expression. This induced changes in the telomere
parameters similar to those seen in high MYCN–expressing
neuroblastoma tissue samples, demonstrating a functional relation-
ship between MYCN expression and 3D telomere organization.
Materials and Methods
Patient Samples
A total of 74 primary neuroblastoma tissue samples, 5μm in thickness,
were obtained from the Health Sciences Centre (Winnipeg, Manitoba,
Canada) (n = 16) andChildren'sOncologyGroup (COG) (n = 58). All of
the tumor samples were derived from untreated patients. Hematoxylin
and eosin–stained sections were used to identify tumor areas. The
experimenters were blinded to the tumor characteristics and outcome data
until after the experiments and measurements were complete. After
decoding this information, it was discovered that only 31 out of the 74
patients had clinical follow-up, and therefore survival analyses for the
whole cohort was not feasible.
Patients were classified according to the International Neuroblastoma
Staging System (INSS) [23] and divided into clinical-genetic risk groups
using the COG risk scoring system [7]. TheMYCN amplification status
was determined by FISH for theCOG samples. TheMYCN amplification
status of theManitoban samples was provided to us by theHealth Sciences
Centre (Winnipeg, Manitoba, Canada). MYCN protein expression was
determined for all samples by tissue immunofluorescence. Tumor
characteristics of the study cohort are shown in Table 1.
This study was approved by Pathology Access Committee for
Tissue (12-0048), Health Science Centre Research Impact committee
(2012:187), CancerCare Manitoba Research Resource Impact
Committee (92-2012), and Research Ethics Board (H2012:391).
Cell Lines
The established neuroblastoma cell lines SHEP and GIMEN were
a gift from Manfred Schwab (The German Cancer Research Center,
Heidelberg, Germany). The cells were cultured in RPMI 1640 with
10% fetal bovine serum with 1% l-glutamine, 1% sodium pyruvate,
and 1% penicillin-streptomycin (Life Technologies Inc., Burlington,
Ontario, Canada) at 37°C in a humidified atmosphere and 5% CO2.
MYCN Transfection of SHEP and GIMEN Neuroblastoma
Cell Lines
SHEP and GIMEN cell lines were transfected withMYCN pUHD
10-3, a gift from Manfred Schwab (The German Cancer ResearchCenter, Heidelberg, Germany), which contains the entire MYCN
coding sequence under the control of an hCMV minimal promoter.
Before transfection, 6 × 105 SHEP and 2 × 105 GIMEN cells were
seeded per well and grown to near confluence. Twenty-four hours
postseeding, cells were cotransfected with TransIT-X2 (MIR6004;
Mirus Bio LLC, Madison, WI) and pmaxGFP (Lonza, Allendale, NJ)
in a ratio of reagent:vector DNA of 2:1, as per the company's
protocol. Cells were cultured in the absence of serum for the first 12
hours. The transfection efficiency was 40% at 15 hours when the cells
were sterile sorted by GFP expression. The sorted transfected cells
were put back into culture and harvested at 72 hours for 3D nuclei
fixation. Mock-transfected cells were used as a control.
3D Nuclei Fixation
Cells were harvested from the cultures of SHEP and GIMEN and
underwent 3D fixation to prepare nuclei for Q-FISH experiments.
3D nuclear fixation was performed according to the protocol
published by Solovei et al. [24].
Immunofluorescence
MYCN immunofluorescence, imaging, and analysis were per-
formed on the neuroblastoma tissue samples and SHEP and GIMEN
cell lines as previously described [25]. The MYCN antibody, a gift
from Manfred Schwab, is described in Wenzel et al. (1991) and was
used at a titer of 1/2000. The slides were imaged using an AxioImager
Z2 microscope (Carl Zeiss, Toronto, Ontario, Canada), an AxioCam
HR charge-coupled device (Carl Zeiss) with a 63×/1.4 oil objective
lens (Carl Zeiss), and DAPI and Cy3 filters (Carl Zeiss). Cy3
exposure times were kept constant between cell lines and between
tissue samples. Thirty cells per experimental replicate were analyzed
for the cell lines, and 100 cells were analyzed in each tumor sample.
We used the following ranges to classify MYCN expression: low as
b2000 relative fluorescence units (RFU), medium as 2000 to 4999
RFU, and high as ≥5000 RFU.
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Nuclei from the neuroblastoma cell lines and 5-μm tissue sections
underwent 3D telomere Q-FISH with a telomere probe (DAKO,
Glostrup, Denmark). The hybridization and image acquisition were
performed according to previously published protocols [26,27]. The
slides were imaged using an AxioImager Z2 microscope (Carl Zeiss), an
AxioCam HR charge-coupled device (Carl Zeiss) with a 63×/1.4 oil
objective lens (Carl Zeiss), and DAPI and Cy3 filters for detection of
nuclear DNA staining and telomere probe signals, respectively (Carl
Zeiss). Cy3 exposure times were kept constant between cell lines and
between tumor samples, and tricolor beads were used to standardize the
bulb strength. Eighty z-stacks for cell lines and 40 z-stacks for tissue at
200 nm each, with Δx = Δy = 106 nm and Δz = 200 nm, were acquired
and then deconvolved using the constrained iterative algorithm [28].
Thirty cells per experimental replicate were analyzed for the cell lines, and
100 cells were analyzed in each tumor sample.
The 3D interphase telomere signals were quantitatively analyzed
with TeloView software [18] to measure the following parameters in
each cell: the number of signals, which corresponds to the number of
telomeres [18]; the intensity of each signal, which correlates with
telomere length [29]; the number of telomeric aggregates, which are
telomeres in close proximity that cannot be resolved as separate
entities at an optical resolution of 200 nm [18]; the nuclear volume
[18]; and the a/c ratio, which is a measurement of the spherical nature
of the telomere distribution [18]. From these measurements, the
following parameters were calculated: the percentage of cells per
patient with aggregates, the number of telomeres per nuclear volume,
and the mean telomere intensity [20,30,31]. With these measure-
ments, we generated a 3D telomere profile for each cell and then
combined the data from multiple cells to create an overall profile for
each tumor sample and each cell line replicate.
Statistical Analysis
Statistical analysis was conducted using SAS 9.3 (SAS Institute
Inc., Cary, NC) software. Hierarchical clustering analysis was used to
subgroup the neuroblastoma tissue samples based on the following
telomere parameters: number of telomeres per cell, number of
telomeric aggregates per cell, percentage of cells per patient with
aggregates, number of telomeres per nuclear volume, and a/c ratio. To
visualize the results of the clustering analysis, canonical discriminant
analysis was performed to generate a plot of can1 versus can2. Can1 is
a calculated value for each tumor sample based on a linear
combination of the clustering variables that has the highest
correlation with the clusters. Can2 is the second linear combination
of the clustering variables uncorrelated with can1 but also showing
correlation with the clusters.
The nested factorial analysis of variance with Tukey
multiple-comparisons test was used to compare the telomere
parameters between the subgroups. The χ2 test was employed to
compare tumor characteristics among the subgroups. Telomere signal
intensities were binned at intervals of 1000 and divided into 3 groups
formed by the 25th and 75th percentiles. In tumor samples, telomeresFigure 1. 3D telomere organization of neuroblastoma subgroups.
parameters of the 74 neuroblastoma tissue samples in our study coh
(blue), and subgroup III (green) are illustrated in a graphical represen
(red) in the nuclei, counterstained with DAPI (blue). Images of multip
(outlined in white in the overview) are illustrated for a neuroblastoma
Scale bars represent 10 μm. The distribution of telomere lengths in
telomeres found at each relative fluorescence intensity interval meawere defined as short with an RFU less than 6000, medium length
with an RFU between 6000 and 11,999, and long with an RFU
greater than or equal to 12,000. In cell lines, telomeres were defined
as short with an RFU less than 7000, medium length with an RFU
between 7000 and 16,999, and long with an RFU greater than or
equal to 17,000. The χ2 test was used to compare the distribution of
short, medium, and long telomeres. The unpaired t test was used to
compare the telomere parameters of the cell lines after MYCN and
mock transfection. P b .05 was considered significant.Results
3D Telomere Organization of Neuroblastoma Tissue Samples
We investigated the 3D telomere organization in 74 neuroblastoma
tissue samples using 3D telomere Q-FISH while blinded to tumor
characteristics. After image acquisition and deconvolution [28], 100
nuclear segments from each tumor were analyzed with TeloView
software [18] to determine the telomere profile associated with that
sample (see Materials and Methods). Hierarchical cluster analysis was
used to stratify the study cohort into subgroups based on the telomere
parameters.
Cluster analysis revealed three unique subgroups, shown graphi-
cally in Figure 1A. The number of neuroblastomas in each subgroup
was as follows: 23 in subgroup I (red), 18 in subgroup II (blue), and
33 in subgroup III (green). A tissue overview as well as a nucleus
illustrating the telomere hybridization from a representative sample in
each of the subgroups is shown in Figure 1, B–G. The scatterplot in
Figure 1H illustrates the distribution of telomere lengths in each
subgroup, with a plot of the number of telomeres found at each
relative fluorescence intensity interval measured.
χ2 analysis revealed a significantly different distribution of telomere
lengths between the subgroups (P b .0001). As shown in Table 2,
there was also a significant difference in the percentage of short,
medium, and long telomeres per cell (P b .001 for all comparisons).
Subgroups I and III are comprised of neuroblastomas with the
greatest percentage of short telomeres per cell (38.7% and 35.9%).
Subgroup II contains tumors with the highest percentage of
medium-length telomeres (42.92%). Tumors with the highest
percentage of long telomeres per cell are found in subgroup III
(31.9%). These findings illustrate that subgroup III, which has a high
percentage of both short and long telomeres, has the most telomere
length heterogeneity.
In addition to measuring individual telomere lengths, 3D telomere
organization calculates telomere parameters that reflect tumor cell
nuclear architecture. Telomeric aggregates are telomeres in close
proximity that cannot be resolved as separate entities at a resolution of
200 nm. The subgroups displayed significantly different numbers of
telomeric aggregates per cell and percentages of cells per patient with
telomeric aggregates (P b .0001 for both comparisons). Subgroup III
was comprised of neuroblastomas with the most telomeric aggregates
(3.4), followed by subgroup II (1.9) and subgroup I (1.1). TheHierarchical cluster analysis based on the measured telomere
ort revealed three unique subgroups. Subgroup I (red), subgroup II
tation (A). 3D telomere Q-FISH of the tumors labels all telomeres
le cells in 2D and 3D renderings of individual representative nuclei
in subgroup I (B & E), subgroup II (C & F), and subgroup III (D & G).
each subgroup is illustrated in a scatterplot (H) of the number of
sured.
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tumors belonging to subgroup II (99.5%), followed by subgroup III
(90.3%) and subgroup I (42.4%).The greatest number of telomeres per cell was observed in the
neuroblastomas found in subgroup III (29.5), followed by subgroup I
(24.6), and subgroup II (16.1) (P b .0001). As the nuclear volume is
Table 2. Statistical Analysis of Telomere Parameters by Neuroblastoma Subgroup
Subgroup I Subgroup II Subgroup III P Value between Subgroups *
Average number of telomeres per nuclear segment (SD †) 24.6 ‡ (3.4) 16.1 (2.3) 29.5 (6.2) b.0001
Average number of telomeric aggregates per nuclear segment (SD) 1.1 (0.1) 1.9 (0.1) 3.4 (1.0) b.0001
Average percentage of cells per patient with telomeric aggregates (SD, %) 42.4 (6.9) 99.5 (0.7) 90.3 (5.2) b.0001
Average nuclear volume (SD, μm3) 351.30 (71.20) 335.78 (76.76) 318.03 (85.55) NS §
Average number of telomeres per nuclear volume (SD) 0.072 (0.013) 0.060 (0.017) 0.092 (0.029) b.0001
Average a/c ratio per cell (SD) 2.57 (0.64) 2.18 (0.56) 3.81 (0.87) b.0001
Average mean telomere intensity per patient (SD, RFU) 8833.0 (341.7) 10,322.6 (649.1) 10,118.3 (472.3) b.0001
Average percentage of short telomeres per cell (SD, %) 38.7 (4.8) 31.0 (4.9) 35.9 (7.3) b.001
Average percentage of medium telomeres per cell (SD, %) 40.0 (3.5) 42.9 (2.7) 32.2 (4.1) b.0001
Average percentage of long telomeres per cell (SD, %) 21.4 (2.7) 26.4 (4.3) 31.9 (4.7) b.0001
* P value determined by one-way analysis of variance.
† Standard deviation.
‡ Data range indicated in Supplementary Table 6.
§ Not significant.
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telomeres per cell, exhibits the most dense telomere distribution: the
average number of telomeres per nuclear volume is 0.092 for subgroup
III, 0.072 for subgroup I, and 0.060 for subgroup II. The a/c ratio, which
measures the spherical nature of the telomere distribution, was also
significantly different between the subgroups (P b .0001). Subgroup III
was comprised of tumors with the largest a/c ratio (3.81), followed by
subgroup I (2.57), and subgroup II (2.18).
In summary, the three subgroups contain neuroblastomas with
unique telomere profiles based on both telomere length and nuclear
organization. The lowest level of telomere dysfunction is seen in
subgroup I, which contains tumors with the fewest telomeric
aggregates per nucleus and lowest percentage of cells per patient
with telomeric aggregates. Subgroup III illustrates the highest level of
telomere dysfunction; it is comprised of tumors with the most
telomeres per nucleus, the highest number of telomeric aggregates per
nucleus, and a high percentage of short telomeres per cell and cells per
patient with telomeric aggregates. A moderate level of telomere
dysfunction is seen in subgroup II, which contains tumors with the
least number of telomeres per cell but has more telomeric aggregates
per cell than subgroup I and the highest percentage of cells per patient
with telomeric aggregates. Telomere dysfunction has been linked to
genomic instability, with higher levels of telomere dysfunction
indicating greater genomic instability [32,33]. Therefore, neuroblas-
tomas with the highest level of genomic instability are found
subgroup III, followed by those in subgroup II, and the tumors in
subgroup I have the lowest level of genomic instability.
Neuroblastomas are known to exhibit intratumor heterogeneity
[34], with increasing diversity of telomere length strongly associated
with disease progression and mortality [35]. Our study supports these
findings as we determined that subgroup III had the greatest standard
deviation in all the telomere parameters, except percentage of cells per
patient with telomeric aggregates and mean telomere intensity;
therefore, subgroup III is comprised of the neuroblastomas with the
greatest intratumor heterogeneity. As tumors with the highest level of
telomere dysfunction are also found in subgroup III, our findings
illustrate that greater intratumor heterogeneity correlates with higher
levels of telomere dysfunction.
Tumor Characteristics in the Neuroblastoma Subgroups
We decoded the neuroblastoma tissue samples to determine the
histopathological characteristics of the tumors in each of the three
subgroups identified by hierarchical cluster analysis of the 3D
telomere parameters. The histology, age at diagnosis, MYCNamplification status, and MYCN expression level of each sample
are summarized in Table 3. χ2 analysis indicated that there was an
association between the cluster to which a tumor belonged and every
tumor characteristic (P b .001 for all comparisons).
The majority of neuroblastomas with unfavorable histology and an
age of diagnosis of more than 18 months were found in subgroup III
(24/35 and 24/33, respectively), whereas most tumors with favorable
histology and an age of diagnosis of less than 18 months were found
in subgroups I and II. All tumors with MYCN amplification and
medium or high levels of MYCN expression were found in subgroup
III. Subgroups I and II were comprised of tumors with low MYCN
expression and no MYCN amplification; however, tumors in
subgroup II had a higher average MYCN expression than those in
subgroup I (1281.09 RFU vs 285.26 RFU, P b .0001). Our data
clearly demonstrate that neuroblastomas with unfavorable histopath-
ological characteristics were found in the subgroups associated with
more telomere dysfunction.
3D Telomere Profiles Versus Current Neuroblastoma
Classification Systems
After decoding the neuroblastoma cohort, we determined the INSS
stage and COG risk score of the tumors in each of the subgroups to
gauge their prognosis (summarized in Table 3). χ2 analysis indicated
that there was an association between the cluster to which a tumor
belonged and both INSS stage and COG risk (P b .0001 for both
comparisons).
The majority of neuroblastomas with stage 1 disease were found in
subgroup I (9/13), which also contained no tumors of stage 4 disease.
Subgroup III was comprised of mainly stage 4 tumors (25/33).
Similar numbers of tumors of all stages were found in subgroup II (3
stage 1, 4 stage 2, 1 stage 3, 5 stage 4, 5 stage 4S). Subgroups I and II
were comprised almost solely of low–COG risk neuroblastomas (21/
23 and 13/18, respectively); however, subgroup II contained three
tumors of high risk. The majority of tumors in subgroup III were of
high COG risk (25/33). Therefore, neuroblastomas of high stage and
poor prognostic risk were found in the subgroups with more telomere
dysfunction.
Changes in 3D Telomere Organization following MYCN
Transfection in Neuroblastoma Cell Lines
3D telomere profiles that indicated more telomere dysfunction
were associated with tumor subgroups with higher MYCN
expression. To determine whether there is a functional relationship
between MYCN expression and 3D telomere organization, we
Table 3. Histopathological Characteristics and Classification of Neuroblastoma Subgroups
Subgroup I (n) Subgroup II (n) Subgroup III (n) P Value *
Histology .0005
Favorable 13 9 6
Unfavorable 4 7 24
Unknown 6 2 3
Age at diagnosis b.0001
b18 months 19 13 9
N18 months 4 5 24
MYCN amplification .0003
No 23 18 22
Yes 0 0 11
MYCN expression b.0001
Low 23 18 2
Medium 0 0 20
High 0 0 11
Stage b.0001
1 9 3 1
2 7 4 0
3 2 1 5
4 0 5 25
4S 5 5 1
Unknown 0 0 1
COG risk score b.0001
Low 21 13 2
Intermediate 1 2 5
High 0 3 25
Unknown 1 0 1
* P value determined by χ2 test.
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expression, SHEP and GIMEN, with a MYCN expression vector. 3D
telomere Q-FISH was conducted on transfected cells and
mock-transfected controls to analyze the nuclei for changes in their
telomere profiles. Transfected cells were sorted to ensure that only
cells with MYCN overexpression were analyzed (see Materials and
Methods). Representative nuclei illustrating the telomere hybridiza-
tion in the control and MYCN-transfected SHEP and GIMEN cell
lines are shown in Figure 2, A–D. The scatterplot in Figure 2E
illustrates the distribution of telomere lengths from each condition, with a
plot of the number of telomeres found at each relative fluorescence
intensity interval measured: SHEP (gray) and GIMEN (black) cell lines
after MYCN (solid lines) and mock (dashed lines) transfection.
The average MYCN expression was significantly higher in the post-
compared to mock-transfection nuclei for both the SHEP and
GIMEN cell lines: 1480.78 versus 6962.54 RFU in the SHEP cell
line (P b .0001) and 1577.19 versus 7839.49 RFU in the GIMEN
cell line (P b .0001). As shown in Table 4, all telomere parameters
were significantly different between the MYCN-transfected and
control cells for both cell lines (P b .05 for all comparisons), except
nuclear volume in both cell lines and percentage of long telomeres in
the GIMEN cell line. Similar to the results seen in low– compared to
higher–MYCN-expressing tumor samples, increased MYCN expres-
sion in the cell lines is associated with an increase in the number of
telomeres, number of telomeric aggregates, and percent of cells with
telomeric aggregates (P b .05 for all comparisons). For both cell lines,
there is a significantly different distribution of telomere lengths
between the control and MYCN-transfected cells (P b .0001), with a
higher percentage of short telomeres correlated with increased MYCN
expression (P b .05 for both comparisons). An increase in the average
number of telomeres per nuclear volume and the a/c ratio indicates
that there is also a different nuclear distribution of the telomeres after
MYCN transfection (P b .05 for all comparisons).In summary, the increased expression of MYCN in both cell lines
following MYCN transfection was associated with altered telomere
profiles that indicated increased telomere dysfunction. These findings
closely parallel those in the neuroblastoma tissue samples and
illustrate a functional relationship between MYCN expression and
3D telomere organization.
Discussion
Using 3D telomere Q-FISH, we determined the telomere profiles of
74 neuroblastoma tissue samples. Statistical hierarchical cluster
analysis identified three patient subgroups based on the measured
3D nuclear telomere parameters. These subgroups had unique levels
of telomere dysfunction. We found that tumors with more telomere
dysfunction were associated with unfavorable histopathologic
characteristics and poor prognosis. Subgroup III, which had the
highest level of telomere dysfunction, clearly identified a group of
neuroblastomas that are of high risk as the majority are stage 4, have
MYCN amplification and high MYCN expression, are greater than 18
months at diagnosis, and have unfavorable histology. Although
tumors in subgroups I and II had similar characteristics, subgroup II
had a higher level of telomere dysfunction and may identify
neuroblastomas with poorer prognosis among this group; accordingly,
subgroup II contained more tumors of higher stage and COG risk
than subgroup I. Previous studies have also found that telomere
profiles can differentiate tumors that are clinically similar. For
example, 3D telomere organization identified recurrent compared to
nonrecurrent Hodgkin's lymphoma patients at diagnosis [31]. And
previously unknown subgroups of glioblastoma that corresponded with
patient survival were discovered using 3D telomere organization [36].
Telomere dysfunction has previously been implicated in neuro-
blastoma pathogenesis. However, previous studies that determined
mean telomere length have been inconclusive as to whether no
change, an increase, or a decrease in telomere length is associated with
poor patient prognosis [13–15]. Our method of 3D telomere analysis
determines the length of each individual telomere in addition to mean
telomere length. All subgroups had a significantly different
distribution of telomere lengths. Interestingly, subgroups II and III
did not have significantly different mean telomere intensities, but
they had unique percentages of short, medium, and long telomeres
(P ≤ .05 for all comparisons, see Supplementary Tables 1-4). This
finding supports using our approach of measuring all individual
telomere lengths as it can detect differences that may be overlooked by
methods that solely determine mean telomere length.
In addition to measuring telomere length, our method also analyzes
the 3D nuclear telomere distribution. The difference in these
parameters indicated that each neuroblastoma subgroup had a unique
nuclear architecture. The a/c ratio measures the spherical nature of
the telomere distribution and correlates with the cell cycle [18,19]. A
higher ratio indicates more cells at the G2/M boundary; therefore,
subgroup III, which has the largest a/c ratio, has the highest level of
cellular proliferation. As telomeres shorten with each cell cycle, high
rates of proliferation can lead to critically short telomeres [37].
Critically short telomeres trigger DNA damage responses and trigger
end-to-end fusions of sister chromatids or of different chromosomes
[38]; subsequently, telomere fusions generate dicentric chromosomes
and breakage-fusion-bridge cycles that lead to chromosome rear-
rangements and ongoing genomic instability [39]. Telomeric
aggregates can represent telomere fusions [39]. Subgroup III also
has the highest number of telomeric aggregates.
Figure 2. 3D telomere organization of neuroblastoma cell lines. 3D telomere Q-FISH labels all telomeres (red) in the SHEP neuroblastoma
cell line mock (A) and MYCN transfection (B) and the GIMEN neuroblastoma cell line mock (C) and MYCN transfection (D). Nuclei are
counterstained with DAPI (blue). The distribution of telomere lengths for each condition is illustrated in a scatterplot (E) of the number of
telomeres found at each relative fluorescence intensity interval measured: SHEP (gray) and GIMEN (black) cell lines after MYCN (solid
lines) and mock (dashed lines) transfection.
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[32,33]. As the neuroblastoma subgroups had different telomere
profiles, they will also have unique levels of genomic instability:
subgroups with higher levels of telomere dysfunction will have greaterTable 4. Statistical Analysis of Telomere Parameters by Neuroblastoma Cell Line
SHEP
Control
SHEP
MYCN-Transfectio
Average MYCN expression per cell (RFU) 1480.78 6962.54
Average number of telomeres per nucleus 41.8 74.9
Average number of aggregates per nucleus 4.9 9.6
Average percentage of cells per replicate with aggregates (%) 71.3 100.0
Average nuclear volume (μm3) 1053.31 1262.03
Average number of telomeres per nuclear volume 0.040 0.060
Average a/c ratio per cell 3.34 6.34
Average percentage of short telomeres per cell (%) 15.1 30.5
Average percentage of medium telomeres per cell (%) 55.7 47.1
Average percentage of long telomeres per cell (%) 29.3 22.4
* P value determined by unpaired t test.
† Not significant.genomic instability. Previously, it has been found that MYCN
amplified neuroblastomas have multiple structural chromosome
aberrations; however, a subset of high-risk MYCN nonamplified
tumors harbor more segmental chromosome aberrations includingn
GIMEN
Control
GIMEN
MYCN-Transfection
P Value between
SHEP Conditions *
P Value between
GIMEN Conditions *
1577.19 7839.49 b.0001 b.0001
85.7 120.3 b.0001 b.01
10.6 15.1 b.05 b.01
80.7 100.0 b.001 b.01
1934.85 2225.43 NS † NS †
0.044 0.054 b.05 b.05
6.32 11.32 b.01 b.05
24.7 39.1 b.001 b.01
52.2 38.5 b.05 b.05
23.1 22.4 b.05 NS
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have the most genomic instability. It has also been proposed that
these high-risk MYCN nonamplified tumors employ the alternative
lengthening of telomeres mechanism [13], a feature of which is
heterogeneous telomere lengths [40]. To compare our data with these
findings, we further examined subgroup III, which contained tumors
with the highest level of genomic instability and highest prognostic
risk. We divided subgroup III into two groups: IIIa, composed of 22
MYCN nonamplified tumors, and IIIb, composed of 11 MYCN
amplified tumors. Subgroup IIIb had tumors with more telomeres
and telomeric aggregates per cell than those in IIIa (P b .0001, see
Supplementary Table 5); however, the tumors in subgroup IIIa had
more telomeres and telomeric aggregates per cell than both subgroups
I and II. The neuroblastomas in subgroups IIIa and IIIb also had a
significantly different distribution of telomere lengths (P b .0001);
MYCN amplified neuroblastomas in IIIb had predominately short
telomeres, whereas MYCN nonamplified tumors in IIIa had similar
percentages of short, medium-length, and long telomeres. Therefore, our
results are consistent with the previous findings of a subgroup of high-risk
MYCN nonamplified neuroblastomas that exhibit a high level of genomic
instability and use alternative lengthening of telomeres.
As tissue samples with MYCN amplification and higher MYCN
expression were associated with more telomere dysfunction, we
examined whether MYCN overexpression could reproduce these
findings. MYCN transfection in two neuroblastoma cell lines with
constitutive low MYCN expression generated changes in their
telomere profiles that were consistent with increased telomere
dysfunction. Therefore, we suggest that MYCN overexpression in
neuroblastoma may cause telomere dysfunction. Previously, it has
been shown that MYC deregulation alters 3D telomere organization
with increases in telomere aberrations and genomic instability [41].
In conclusion, this study demonstrates that 3D telomere
organization can be used to subgroup neuroblastomas. Classifying
neuroblastomas based on the level of telomere dysfunction is a novel
approach for this cancer. Similar to previous studies in acute myeloid
leukemia, multiple myeloma, glioblastoma, and Hodgkin's lympho-
ma [20–22,36], we found telomere profiles in neuroblastoma to
correlate with tumor characteristics and patient prognosis. We
propose that 3D telomere organization may be a novel prognostic
marker in neuroblastoma, and further studies are needed to validate
its potential.
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